Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Fineline Cube May 18, 2026
Company Deals Hospital Medical Device

Siemens Healthineers Collaborates with MGH to Advance Theranostics Applications

Fineline Cube Jun 25, 2025

Siemens Healthineers AG (ETR: SHL), a Germany-based medical device giant, has entered into a research...

Company Drug

FDA Approves AstraZeneca’s Datopotamab deruxtecan for EGFR-Mutated NSCLC

Fineline Cube Jun 25, 2025

The US Food and Drug Administration (FDA) this week approved Datopotamab deruxtecan (Dato-DXd), a TROP-2-targeted...

Company Drug

TransThera Sciences’ Tinengotinib Gains FDA Fast Track for mCRPC Treatment

Fineline Cube Jun 25, 2025

China-headquartered TransThera Sciences (Nanjing) Inc., (HKG: 2617), which listed in Hong Kong this week, announced...

Company Deals Drug

XtalPi Signs LOI With DoveTree for AI-Powered Drug Development

Fineline Cube Jun 25, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), announced the signing of a Letter...

Company Drug

Merck’s Prevymis Approved in China for Pediatric CMV Prevention

Fineline Cube Jun 25, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that its novel non-nucleoside...

Company Drug

Sansure Biotech Wins NMPA Approval for Fungal Infection Detection Kit

Fineline Cube Jun 24, 2025

China’s National Medical Products Administration (NMPA) has approved Sansure Biotech Inc.’s (SHA: 688289) Pneumocystis jirovecii,...

Company Medical Device

Broncus Medical Wins NMPA Approval for BroncAblate RFA System Console

Fineline Cube Jun 24, 2025

Shanghai and Hangzhou (China), and San Jose and Seattle (United States)-based Broncus Medical (HKG: 2216)...

Policy / Regulatory

NHSA Implements Region-Based Pricing System for Medical Services

Fineline Cube Jun 24, 2025

China’s National Healthcare Security Administration (NHSA) this week issued the “Notice on Optimizing Medical Service...

Company Deals

Insilico Medicine Partners with UAEU to Drive Biotech Innovation in the Middle East

Fineline Cube Jun 24, 2025

China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine this week entered into a strategic Memorandum...

Company Deals

Bio-Thera Partners with SteinCares for Biosimilar Commercialization in Latin America

Fineline Cube Jun 24, 2025

Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) and Costa Rica-based SteinCares have entered into a licensing...

Company Drug

Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment

Fineline Cube Jun 24, 2025

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) announced that its clinical trial...

Company Drug R&D

Simcere Halts R&D on Alzheimer’s Drug Candidates Amid Pipeline Setbacks

Fineline Cube Jun 24, 2025

Simcere Pharmaceutical Group (HKG: 2096) has reportedly discontinued research and development of its Alzheimer’s disease...

Company Drug

Yifan Pharma Wins NMPA Approval for Norditropin Biosimilar Trial

Fineline Cube Jun 24, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that it has received clinical trial approval...

Company Drug

GSK’s Linerixibat Accepted for EMA Review for Cholestatic Pruritus in PBC

Fineline Cube Jun 24, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted the...

Company Drug

Sanofi’s Sarclisa Recommended for EU Approval in Newly Diagnosed Multiple Myeloma

Fineline Cube Jun 24, 2025

France major Sanofi (NASDAQ: SNY) announced that the European Medicines Agency’s (EMA) Committee for Medicinal...

Policy / Regulatory

Beijing Tightens Price Risk Management for Scarce Medications

Fineline Cube Jun 24, 2025

The Beijing Municipal Medical Insurance Bureau issued the “Notice on Further Strengthening Price Risk Management...

Company Deals

Cloudbreak Pharma’s IPO Raises HKD 522M for Ophthalmic Drug Development

Fineline Cube Jun 24, 2025

Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of...

Company Deals

Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study

Fineline Cube Jun 24, 2025

US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK/SYK...

Company Drug

Novo Nordisk’s Ozempic Gets Positive CHMP Opinion for Peripheral Artery Disease

Fineline Cube Jun 24, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency’s (EMA) Committee for...

Company Deals

Illumina to Acquire SomaLogic for $350M to Expand Proteomics Tech Integration

Fineline Cube Jun 24, 2025

US major Illumina (NASDAQ: ILMN) announced plans to acquire SomaLogic, a leader in data-driven proteomics...

Posts pagination

1 … 139 140 141 … 667

Recent updates

  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.